Sir Gregory Winter, CBE, FRS, FMedSci

Non-executive Director of Bicycle Therapeutics; Trustee of the Newton Trust and the Kennedy Trust for Rheumatology Research.

Country: United Kingdom

Sir Gregory Winter is a genetic engineer and is best known for his research and inventions relating to humanised and human therapeutic antibodies. Sir Gregory is a graduate of Trinity College, Cambridge and was a Senior Research Fellow before becoming Master.

His research career was based almost entirely in Cambridge at the Medical Research Council’s Laboratory of Molecular Biology and the Centre for Protein Engineering. During this time he also founded three Cambridge biotech companies based on his inventions: Cambridge Antibody Technology (acquired by AstraZeneca), Domantis (acquired by GlaxoSmithKline) and Bicycle Therapeutics.

Sir Gregory was awarded the 2018 Nobel Prize in Chemistry “for the phage display of peptides and antibodies” along with George Smith and Frances Arnold.

Sir Gregory is a non-executive Director of Bicycle Therapeutics, and a Trustee of the Newton Trust and the Kennedy Trust for Rheumatology Research.